Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ziprasidone - Pfizer

Drug Profile

Ziprasidone - Pfizer

Alternative Names: Captisol-enabled IV-Ziprasidone; CP-88059-01; CP-88059-1; Geodon; ME-2112; RQ-00000003; Zeldox; Ziprasidone hydrochloride; Ziprasidone mesylate

Latest Information Update: 27 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Meiji Seika Pharma; Pfizer; RaQualia Pharma
  • Class Antipsychotics; Mood stabilisers; Piperazines; Thiazoles
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Schizophrenia
  • No development reported Anxiety disorders
  • Discontinued Bipolar depression

Most Recent Events

  • 23 Jul 2020 Pfizer terminates phase III trial in Bipolar disorders (In adolescents, In Children) in USA, Philippines and Ukraine due to inputs from US FDA (NCT02075047)
  • 06 Jan 2020 Ziprasidone is still in phase III for Bipolar disorders in Japan (PO) (Meiji Seika Pharma pipeline, January 2020)
  • 06 Sep 2019 Meiji Seika Pharma completes a phase III trials for Schizophrenia in Japan prior to September 2019 (PO, Capsule) (JapicCTI-152821)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top